ERC1671 (gliovac) is an intriguing immunotherapy that has been tested in combination with bevacizumab, and it consists of autologous inactivated tumor cells lysate from the patient to be treated, inactivated tumor cells and lysate from three other GBM patients, cyclophosphamide to inhibit local immunosuppression, and GM-CSF as an adjuvant to enhance the immune response (147). The gene discussed is CSF2; the disease is neoplasm.